| Literature DB >> 35714675 |
William G Wierda1, Jennifer Brown2, Jeremy S Abramson3, Farrukh Awan4, Syed F Bilgrami5, Greg Bociek6, Danielle Brander7, Asher A Chanan-Khan8, Steve E Coutre9, Randall S Davis10, Herbert Eradat11, Christopher D Fletcher12, Sameh Gaballa13, Armin Ghobadi14, Muhammad Saad Hamid15, Francisco Hernandez-Ilizaliturri16, Brian Hill17, Paul Kaesberg18, Manali Kamdar19, Lawrence D Kaplan20, Nadia Khan21, Thomas J Kipps22, Shuo Ma23, Anthony Mato24, Claudio Mosse25, Stephen Schuster26, Tanya Siddiqi27, Deborah M Stephens28, Chaitra Ujjani29, Nina Wagner-Johnston30, Jennifer A Woyach31, J Christine Ye32, Mary A Dwyer33, Hema Sundar33.
Abstract
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35714675 DOI： 10.6004/jnccn.2022.0031
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 12.693